Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
March 10, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
March 07, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer
March 06, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with L
Plus Therapeutics Announces New Employment Inducement Grants
March 05, 2025 16:01 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Announces New Employment Inducement Grants
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
March 04, 2025 14:06 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
March 04, 2025 06:35 ET
|
Y-mAbs Therapeutics, Inc.
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
February 24, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
February 20, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
February 18, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
December 05, 2024 16:21 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet...